近7天，经纬辉开股价呈现小幅波动。根据内部数据库，截至2026年2月13日收盘，股价报8.48元，当日 跌幅0.47%，区间（2月9日至2月13日）累计涨幅2.54%，振幅6.29%。资金流向显示，2月13日主力净流 出约1254.84万元，散户资金呈净流入状态。公司当前市盈率（TTM）为负值，反映盈利承压，但股价 波动整体温和，未出现异常炒作迹象。 以上内容基于公开资料整理，不构成投资建议。 经纬辉开于2026年2月12日晚间发布公告，宣布召开第六届第十七次董事会会议，审议并通过了聘任王 蕾女士为公司副总经理、财务负责人的议案。此次人事变动涉及原董事、副总经理HOO YONG KEONG和原副总经理、财务负责人蒋爱平的辞任，均因工作调整原因，二人将继续在公司子公司任 职。此前，公司于2月10日召开了第六届第十六次董事会会议，审议了聘任总经理等议案。这些治理调 整可能影响公司管理稳定性，但公告未披露具体业务影响。 股票近期走势 经济观察网 根据近期公开信息，经纬辉开（300120）（股票代码：300120）在近7天（2026年2月7日至 2月14日）的主要热点集中于公司治理变动和二级市场表现。以下是基于最新公 ...

Core Points - The sudden announcement of the death of Yin Zhenglong, the controlling shareholder and chairman of Shanhe Pharmaceutical Excipients, occurred on August 26, 2025, at the age of 60 [1][5][7] - Yin Zhenglong held 63,057,454 shares, accounting for 26.90% of the company's total shares, making him the controlling shareholder [7] - The company stated that Yin Zhenglong's death would not affect the normal operation of the board of directors, and the management team would continue to perform their duties [9] Company Background - Shanhe Pharmaceutical Excipients was founded in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients, currently holding a leading position in the domestic market [11] - The company was successfully listed on the Shenzhen Stock Exchange in May 2015, with a current market value of approximately 3.28 billion yuan [11] - Under Yin Zhenglong's leadership, the company grew from a small local pharmaceutical factory to a publicly listed company [10] Financial Performance - For the first half of 2025, Shanhe Pharmaceutical Excipients reported a revenue of 471 million yuan, a year-on-year increase of 4.65%, while the net profit attributable to shareholders decreased by 2.61% to approximately 93 million yuan [12][13] - The company reported a significant increase in cash flow from operating activities, which rose by 108.53% compared to the previous year [13] - The basic earnings per share decreased by 2.44% to 0.40 yuan, while diluted earnings per share fell by 5.00% to 0.38 yuan [13]